Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Supriya Narang

Psychiatry Timonium, MD Medical Doctor

NPI 1083689293 CMS profile 276211

1925 Greenspring Dr, Timonium, MD 21093

Open in the dashboard

General payments

$4,723

278 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Supriya Narang of Timonium, MD is reported in the CMS Open Payments database as having received $4,723 across 278 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $41 2
2023 General $565 26
2022 General $587 30
2021 General $1,102 56
2020 General $880 54
2019 General $1,548 110

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Supriya Narang
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Supriya Narang were reported at $41. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Supriya Narang Psychiatry median Middle half National median
2019 $1,548 $184 $59–$605 $163
2020 $880 $119 $36–$372 $114
2021 $1,102 $143 $43–$576 $132
2022 $587 $153 $50–$590 $149
2023 $565 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $41 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $720 41 payments
  2. Janssen Pharmaceuticals, Inc $651 36 payments
  3. Alkermes, Inc. $444 21 payments
  4. Teva Pharmaceuticals USA, Inc. $411 25 payments
  5. Lundbeck LLC $370 24 payments
  6. Allergan Inc. $351 31 payments
  7. Neurocrine Biosciences, Inc. $345 21 payments
  8. Sunovion Pharmaceuticals Inc. $317 19 payments
  9. ITI, Inc. $285 14 payments
  10. AbbVie, Inc. $269 14 payments
  11. Other $560 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,666 274 payments
  2. Education $57 4 payments
Products named General payments · program years 2019–2025
  1. ABILIFY MAINTENA $552 30 payments
  2. INVEGA SUSTENNA $488 25 payments
  3. INVEGA TRINZA $453 23 payments
  4. REXULTI $432 25 payments
  5. ARISTADA Cns $422 20 payments
  6. ARISTADA Cns $422 20 payments
  7. SPRAVATO $371 19 payments
  8. VRAYLAR $351 31 payments
  9. AUSTEDO $341 22 payments
  10. ARISTADA INITIO $338 17 payments
  11. Other $3,220 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

4,761

Median for Psychiatry: 574

Drug cost

$629,450

Median for Psychiatry: $27,624

Branded share of claims

11.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 20 $131,846
Invega Sustenna Paliperidone Palmitate Brand 40 $131,455
Abilify Maintena Aripiprazole Brand 18 $52,515
Vraylar Cariprazine Hcl Brand 28 $43,314
Risperdal Consta Risperidone Microspheres Brand 17 $38,098
Aripiprazole Generic 105 $34,242
Clozapine Generic 316 $22,079
Lybalvi Olanzapine/Samidorphan Malate Brand 12 $19,581
Lurasidone Hcl Generic 63 $19,223
Fluphenazine Hcl Generic 53 $13,804

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$50,016

Medicare's payments for the services billed

Medicare patients

134

Average age 54

Services billed

663

74 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Diabetes 37%
Depression 37%
Arthritis 25%
COPD 16%
Chronic kidney disease 15%
Ischemic heart disease 10%
Cancer 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record